Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $7.88 Consensus Target Price from Analysts

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $7.88.

Several brokerages have recently weighed in on GOSS. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a report on Monday, May 20th. Wedbush reiterated an “outperform” rating and issued a $4.00 price target on shares of Gossamer Bio in a report on Wednesday, May 8th. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target on shares of Gossamer Bio in a report on Wednesday, March 27th. Oppenheimer began coverage on Gossamer Bio in a report on Tuesday. They issued an “outperform” rating and a $9.00 price target on the stock. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $8.00 price target on shares of Gossamer Bio in a report on Monday, June 17th.

Insiders Place Their Bets

In other news, CEO Faheem Hasnain acquired 372,000 shares of Gossamer Bio stock in a transaction on Friday, June 21st. The shares were bought at an average cost of $0.67 per share, for a total transaction of $249,240.00. Following the acquisition, the chief executive officer now directly owns 5,408,073 shares of the company’s stock, valued at approximately $3,623,408.91. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sivia Capital Partners LLC purchased a new position in shares of Gossamer Bio in the 1st quarter valued at $29,000. SG Americas Securities LLC purchased a new position in shares of Gossamer Bio in the 1st quarter valued at $34,000. Financial Advocates Investment Management increased its holdings in shares of Gossamer Bio by 35.0% in the 4th quarter. Financial Advocates Investment Management now owns 98,350 shares of the company’s stock valued at $90,000 after acquiring an additional 25,500 shares during the period. Citigroup Inc. increased its holdings in shares of Gossamer Bio by 9,916.9% in the 3rd quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock valued at $164,000 after acquiring an additional 194,768 shares during the period. Finally, Kynam Capital Management LP purchased a new position in shares of Gossamer Bio in the 3rd quarter valued at $208,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Price Performance

NASDAQ:GOSS opened at $0.95 on Tuesday. The firm has a market capitalization of $215.38 million, a price-to-earnings ratio of -0.90 and a beta of 1.90. Gossamer Bio has a 1 year low of $0.45 and a 1 year high of $1.88. The business has a 50 day simple moving average of $0.67 and a 200-day simple moving average of $0.92. The company has a debt-to-equity ratio of 7.37, a current ratio of 7.13 and a quick ratio of 7.13.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). Equities analysts forecast that Gossamer Bio will post -0.35 EPS for the current year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.